کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3275480 | 1208508 | 2012 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Les inhibiteurs de la CETP
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
غدد درون ریز، دیابت و متابولیسم
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
The concept that HDL-cholesterol raising through inhibition of cholesteryl ester transfer protein (CETP) may decrease the residual cardiovascular risk observed on statin therapy has been challenged by the failure of the CETP inhibitor, torcetrapib. Indeed even if CETP contributes to an atherogenic lipoprotein profile by redistributing cholesteryl esters from HDL toward apoB containing lipoproteins, this lipid transfer may also have antiatherogenic properties. However, off-target effects of torcetrapib on blood pressure, unrelated to CETP inhibition, were believed to provide an explanation for the failure of this drug. Other CETP inhibitors, such as dalcetrapib and anacetrapib, are unlikely to increase blood pressure. Results of large ongoing clinical end-point trials are necessary to provide convincing evidence that, in addition to raising HDL-cholesterol, CETP inhibition is a viable strategy in addition to statin therapy in high-risk patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Médecine des Maladies Métaboliques - Volume 6, Issue 1, February 2012, Pages 43-48
Journal: Médecine des Maladies Métaboliques - Volume 6, Issue 1, February 2012, Pages 43-48
نویسندگان
M. Farnier,